Study Details
Testing the Study Drug Ritlecitinib for People with Vitiligo
(IRB#: IRB_00171778)
Vitiligo causes the loss of skin color and blotches of the skin. This study will test a drug called Ritlecitinib for people with this condition. The study wants to see if it will help people and is safe. People in the study will be randomly chosen to receive Ritlecitinib or a placebo. A placebo looks like the drug but does not have the medication. Being in the study requires attending in-person visits at the study clinic and lasts about 2 years. Medical tests will be done to track the health of participants.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 18 years and older
- Diagnosis of nonsegmental (general) vitiligo for at least 3 months before participation
- Active vitiligo with at least one present lesion
- Stable vitiligo based on absent signs of the active disease
- Able to attend in person at the study clinic
Exclusion Criteria
- Any medical condition affecting participation within the prior year
- Any mental health condition affecting participation within the prior year
- Active suicidal behavior
- Current or history of other specific infections that affect participation
Will I be paid for my time?
Yes
IRB#: IRB_00171778
PI: Jamie Rhoads
Department: DERMATOLOGY
Approval Date: 2024-06-26 06:00:00
Specialties: Dermatology